Thus, a new generation of bisphosphonate, zoledronate (zoledronic acid, Zometa), downregulates the expression levels of SDC1, SDC2, and GPC1 and upregulates the expression of SDC4 in breast cancer cells of low and high metastatic capability [144]. Here, SDC2 is linked to breast cancer.